asimov.com

Sivuston tiedot asimov.com

Asimov — Intelligent Design

 Luotu Maaliskuu 30 2026 15:19 PM

Vanhentuneet tiedot? PÄIVITÄ !

Pisteet 56/100

SEO Sisältö

Otsikko

Asimov — Intelligent Design

Pituus : 27

Täydellistä, otsikkosi sisältää väliltä 10 ja 70 kirjainta.

Kuvaus

Asimov builds tools to program living cells. We're integrating mammalian synthetic biology with computer-aided design to advance therapeutic applications.

Pituus : 154

Hienoa, sinun meta-kuvauksesi sisältää väliltä70 ja 160 kirjainta.

Avainsanat

Erittäin huono. Emme löytäneen meta -sanoja sivultasi. Käytä Tätä ilmaista meta-kuvaus generaattoria lisätäksesi kuvauksen.

Open Graph (OG-tägit) tarjoavat mahdollisuuden merkitä verkkosivustojen sisältöä meta-tiedoilla.

Hienoa, sinun sivu käyttää hyödyksi Open Graph protokollaa (OG meta prop).

Omaisuus Sisältö
type website

Otsikot

H1 H2 H3 H4 H5 H6
1 87 80 0 0 0
  • [H1] Intelligent designof living systems
  • [H2] Enabling the design and manufacture of advanced therapies
  • [H2] Our approach
  • [H2] How to work with us
  • [H2] Two ways to work with us
  • [H2] Built by genetic designers, for biotech builders
  • [H2] Supported by top investors and US research agencies
  • [H2] Partnered with over 25 companies, from small biotechs to big pharma
  • [H2] In the press
  • [H2] Asimov Launches RNA Edge, a Lab-in-the-Loop Platform for AI Optimization of RNA Therapeutic Candidates
  • [H2] Asimov Launches RNA Edge, a Lab-in-the-Loop Platform for AI Optimization of RNA Therapeutic Candidates
  • [H2] Asimov Announces Cell Line Development Partnership with Score Pharma to Advance Biosuperior Antibody Therapeutics
  • [H2] Asimov Announces Cell Line Development Partnership with Score Pharma to Advance Biosuperior Antibody Therapeutics
  • [H2] Asimov and AGC Biologics Team Up to Provide a Cost-Effective, Simplified, and Secure Manufacturing Approach for Viral Vector Production
  • [H2] Asimov and AGC Biologics Team Up to Provide a Cost-Effective, Simplified, and Secure Manufacturing Approach for Viral Vector Production
  • [H2] Asimov Launches CHO Edge Rapid Pools to Bridge Biologics Discovery and CMC with Predictive Stable Expression
  • [H2] Asimov Launches CHO Edge Rapid Pools to Bridge Biologics Discovery and CMC with Predictive Stable Expression
  • [H2] Optimizing Bispecific Antibody Expression with Amgen
  • [H2] Optimizing Bispecific Antibody Expression with Amgen
  • [H2] Asimov Launches Stable AAV Producer Cell Lines, Setting a New Standard for Viral Vector Manufacturing
  • [H2] Asimov Launches Stable AAV Producer Cell Lines, Setting a New Standard for Viral Vector Manufacturing
  • [H2] Asimov Announces Cell Line Development Partnership with Ottimo Pharma to Accelerate Cancer Immunotherapy’s Path to Clinic
  • [H2] Asimov Announces Cell Line Development Partnership with Ottimo Pharma to Accelerate Cancer Immunotherapy’s Path to Clinic
  • [H2] Asimov Enters into Agreement with BARDA's BioMaP Consortium to Advance Production of Medical Countermeasures Against Ebola and Deadly Viruses
  • [H2] Asimov Enters into Agreement with BARDA's BioMaP Consortium to Advance Production of Medical Countermeasures Against Ebola and Deadly Viruses
  • [H2] Asimov Announces IND Approval and Clinical Dosing of Bispecific Antibody Produced Using CHO Edge Expression System
  • [H2] Asimov Announces IND Approval and Clinical Dosing of Bispecific Antibody Produced Using CHO Edge Expression System
  • [H2] Cytiva and Asimov collaborate on next generation cell line design and process development
  • [H2] Cytiva and Asimov collaborate on next generation cell line design and process development
  • [H2] LOTTE BIOLOGICS and Asimov Announce Partnership for Accelerated Cell Line Development And Scaling to GMP Manufacturing
  • [H2] LOTTE BIOLOGICS and Asimov Announce Partnership for Accelerated Cell Line Development And Scaling to GMP Manufacturing
  • [H2] Novo Nordisk license CHO Edge System
  • [H2] Novo Nordisk license CHO Edge System
  • [H2] Asimov and RevOpsis Therapeutics Sign Licensing Agreement for High Titer Multispecific-Expressing Cell Line
  • [H2] Asimov and RevOpsis Therapeutics Sign Licensing Agreement for High Titer Multispecific-Expressing Cell Line
  • [H2] Asimov launches AAV Edge, a suite of AI models, host cells, and genetic tools for end-to-end gene therapy development
  • [H2] Asimov launches AAV Edge, a suite of AI models, host cells, and genetic tools for end-to-end gene therapy development
  • [H2] Asimov introduces its AI-driven 4th generation CHO Edge System with increased titer guarantee
  • [H2] Asimov introduces its AI-driven 4th generation CHO Edge System with increased titer guarantee
  • [H2] Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service
  • [H2] Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service
  • [H2] Asimov launches LV Edge Packaging System to optimize lentivirus production
  • [H2] Asimov launches LV Edge Packaging System to optimize lentivirus production
  • [H2] Announcing Asimov Press
  • [H2] Announcing Asimov Press
  • [H2] Asimov Labs
  • [H2] Asimov Labs
  • [H2] Lift Off
  • [H2] Lift Off
  • [H2] Asimov to Present Data on AI-Designed Tissue Specific Promoters at Upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
  • [H2] Asimov to Present Data on AI-Designed Tissue Specific Promoters at Upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
  • [H2] Asimov Partners With iGEM to Support the Next Generation of Synthetic Biologists
  • [H2] Asimov Partners With iGEM to Support the Next Generation of Synthetic Biologists
  • [H2] Asimov and Center for Breakthrough Medicines Form Strategic Partnership for Viral Vector Production
  • [H2] Asimov and Center for Breakthrough Medicines Form Strategic Partnership for Viral Vector Production
  • [H2] Asimov Raises $200 Million to Advance Therapeutics Design and Manufacturing with Synthetic Biology
  • [H2] Asimov Raises $200 Million to Advance Therapeutics Design and Manufacturing with Synthetic Biology
  • [H2] Drug Manufacture Has One Huge Flaw. This Synthetic Biology Startup Just Raised $200m To Fix It.
  • [H2] Drug Manufacture Has One Huge Flaw. This Synthetic Biology Startup Just Raised $200m To Fix It.
  • [H2] Asimov Selected by DARPA to Develop Artificial Intelligence Design Engine for Synthetic Biology
  • [H2] Asimov Selected by DARPA to Develop Artificial Intelligence Design Engine for Synthetic Biology
  • [H2] MIT Startup Exchange Names Asimov to STEX25
  • [H2] MIT Startup Exchange Names Asimov to STEX25
  • [H2] MIT Spinout Asimov Implements Programming Language for Cells
  • [H2] MIT Spinout Asimov Implements Programming Language for Cells
  • [H2] How Programmable DNA Strands Could Control Healing
  • [H2] How Programmable DNA Strands Could Control Healing
  • [H2] The automatic-design tools that are changing synthetic biology
  • [H2] The automatic-design tools that are changing synthetic biology
  • [H2] Biologists would love to program cells as if they were computer chips
  • [H2] Biologists would love to program cells as if they were computer chips
  • [H2] How Cambridge Startup Asimov Is Doing Business With 'Genetic Circuits'
  • [H2] How Cambridge Startup Asimov Is Doing Business With 'Genetic Circuits'
  • [H2] Bio-programming toolkit maker Asimov launches with $4.7M from Andreessen Horowitz
  • [H2] Bio-programming toolkit maker Asimov launches with $4.7M from Andreessen Horowitz
  • [H2] Andreessen Horowitz Backs Asimov’s Synthetic Biology CAD Software
  • [H2] Andreessen Horowitz Backs Asimov’s Synthetic Biology CAD Software
  • [H2] Andreessen Horowitz leads seed round in MIT-born 'genetic circuits' startup
  • [H2] Andreessen Horowitz leads seed round in MIT-born 'genetic circuits' startup
  • [H2] Genetic Circuits Startup Asimov Raises Seed Round Led by Andreessen Horowitz
  • [H2] Genetic Circuits Startup Asimov Raises Seed Round Led by Andreessen Horowitz
  • [H2] Asimov
  • [H2] Asimov
  • [H2] Cellular Circuit Computes with DNA
  • [H2] Cellular Circuit Computes with DNA
  • [H2] A programming language for living cells
  • [H2] A programming language for living cells
  • [H2] We're hiring at the intersection of biology, engineering, and machine learning.
  • [H3] Biologics
  • [H3] Cell Therapies
  • [H3] Gene Therapies
  • [H3] Host cells
  • [H3] Genetic parts library
  • [H3] Design software
  • [H3] Host cell lines
  • [H3] Genetic parts library
  • [H3] Design software
  • [H3] We provide tools for you to develop a cell line
  • [H3] We develop a cell line for you
  • [H3] We provide tools for you to develop a cell line
  • [H3] You design DNA
  • [H3] We build DNA
  • [H3] You transfect cells
  • [H3] You request producer cells
  • [H3] We do cell line development
  • [H3] We share progress
  • [H3] We ship you producer cell banks
  • [H3] We provide tools for you to develop a cell line
  • [H3] We develop a cell line for you
  • [H3] We provide tools for you to develop a cell line
  • [H3] You design DNA
  • [H3] We build DNA
  • [H3] You transfect cells
  • [H3] You request producer cells
  • [H3] We do cell line development
  • [H3] We share progress
  • [H3] We ship you producer cell banks
  • [H3] We develop a cell line for you
  • [H3] We provide tools for you to develop a cell line
  • [H3] You design DNA
  • [H3] We build DNA
  • [H3] You transfect cells
  • [H3] You request producer cells
  • [H3] We do cell line development
  • [H3] We share progress
  • [H3] We ship you producer cell banks
  • [H3] We transfer our platform to your lab
  • [H3] We ship you host cells and grant software access
  • [H3] You design DNA
  • [H3] We ship DNA to you
  • [H3] You perform cell line development
  • [H3] We perform services in our lab
  • [H3] You request a stable cell line
  • [H3] We perform cell line and process development
  • [H3] We collaborate and share progress
  • [H3] We ship you clonal, stable cell lines
  • [H3] We provide tools for you to develop a cell line
  • [H3] We develop a cell line for you
  • [H3] We provide tools for you to develop a cell line
  • [H3] You design DNA
  • [H3] We build DNA
  • [H3] You transfect cells
  • [H3] You request producer cells
  • [H3] We do cell line development
  • [H3] We share progress
  • [H3] We ship you producer cell banks
  • [H3] We transfer our platform to your lab
  • [H3] We develop a cell line for you
  • [H3] We ship you host cells and grant software access
  • [H3] You design DNA
  • [H3] We ship DNA to you
  • [H3] You perform cell line development
  • [H3] You request producer cells
  • [H3] We do cell line development
  • [H3] We share progress
  • [H3] We ship you producer cell banks
  • [H3] We perform services in our lab
  • [H3] We provide tools for you to develop a cell line
  • [H3] You design DNA
  • [H3] We build DNA
  • [H3] You transfect cells
  • [H3] You request a stable cell line
  • [H3] We perform cell line and process development
  • [H3] We collaborate and share progress
  • [H3] We ship you clonal, stable cell lines
  • [H3] Everything you need
  • [H3] From our lab to yours
  • [H3] We use our own platform every day

Kuvat

Emme löytäneet 285 yhtään kuvia tältä sivustolta.

214 Alt-attribuutit on tyhjiä tai poistettu. Lisää vaihtoehtoista tekstiä niin, että hakukoneet ymmärtävät paremmin kuvatesi sisällön.

Kirjain/HTML suhde

Suhde : 11%

Tämän sivun / sivujen suhde teksti -> HTML on vähemmäinkuin 15 prosenttia, tämä tarkoittaa sitä, että luultavasti tulee tarvitsemaan lisää teksti sisältöä.

Flash

Täydellistä!, Flash-sisältöä ei ole havaittu tällä sivulla.

html-dokumentti sivun sisälle (Iframe)

Erittäin huono, Web-sivuilla on Iframes, tämä tarkoittaa, että Iframe-sisältöä ei voida indeksoida.

URL- Uudelleenkirjoitus

Hyvä. Sinun linkkisi näyttävät puhtailta!

Alleviivaa URL-osoitteet

Täydellistä! URL-osoitteissasi ei ole merkintöjä.

Sivun linkit

Löysimme yhteensä 4 linkit jotka sisältää 0 linkit tiedostoihin

Ankkuri Tyyppi Mehu
Biologics Sisäinen Antaa mehua
Cell Therapies Sisäinen Antaa mehua
Gene Therapies Sisäinen Antaa mehua
Sign up Sisäinen Antaa mehua

SEO avainsanat

Avainsana pilvi

design asimov line software cells development read more blog cell

Avainsanojen johdonmukaisuus

Avainsana Sisältö Otsikko Avainsanat Kuvaus Otsikot
cell 113
more 86
asimov 85
read 79
line 79

Käytettävyys

Url

Sivusto : asimov.com

Pituus : 10

Pikkukuva (favicon)

Hienoa, sinun sivulla on favicon (pikakuvake).

Tulostettavuus

Emme löytäneet tulostusystävällistä CSS-palvelua.

Kieli

Hyvä. Ilmoitettu kieli on en.

Metatietosanastostandardi informaatio (DC)

Tämä sivu ei käytä hyödyksi (DublinCore =DC) metatietosanastostandardi informaatiokuvausta.

Dokumentti

(dokumenttityyppi); Merkistökoodaus

HTML 5

Koodaus/tietojenkäsittely

Täydellistä. Ilmoitettu asiakirjan merkkijono on UTF-8.

W3C Voimassaolo

Virheet : 0

Varoitukset : 0

Sähköpostin yksityisyys

Varoitus! Ainakin yksi sähköpostiosoite on löytynyt tavallisesta tekstistä. Käytä tätä ilmaista antispam suojausta piilottaaksesi sähköpostiosoitteet spämmereiltä.

HTML Epäonnistui

Hienoa! Emme ole löytäneet vanhentuneita HTML-tunnisteita HTML-koodistasi.

Nopeus neuvot

Erinomaista, verkkosivustosi ei käytä sisäkkäisiä taulukoita.
Harmillista, Sivustosi käyttää sisäisiä tyylejä.
Hienoa, Sivustossasi on muutamia CSS-tiedostoja.
Harmillista, sivustossasi on liikaa JavaScript-tiedostoja (enemmänkuin6).
Täydellistä, Sivustosi hyödyntää gzipia.

Mobiili

Mobiili optimointi

Apple-kuvake
Meta Viewport -tunniste
Flash sisältö

Optimoi

XML Sivukartta

Hienoa, sivustossasi on XML-sivukartta.

https://www.asimov.com/sitemap.xml

Robots.txt

https://asimov.com/robots.txt

Hienoa, sivustossasi on robots.txt-tiedosto.

Analyysit

Hienoa, sivustossasi on analyysityökalu.

   Google Analytics

Sivuston nopeus

Laite
Luokat

Free SEO Testing Tool

Free SEO Testing Tool On ilmainen SEO työkalu, joka auttaa sinua analysoimaan Web-sivusi